Literature DB >> 17674313

Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera.

Susama Verma1, Katia Cikurel, Igor J Koralnik, Susan Morgello, Charlotte Cunningham-Rundles, Zelig R Weinstein, Christine Bergmann, David M Simpson.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is a usually fatal cerebral white matter disease found in patients with human immunodeficiency virus infection and other immunocompromised states. We present the case of a 63-year-old woman with polycythemia vera who developed a progressive focal neurological deficit with white matter abnormalities on magnetic resonance images of the brain that was proved on biopsy to be PML. She was treated with the serotonin reuptake inhibitor mirtazapine and remains neurologically stable, with resolution of cerebral lesions, >2 years after diagnosis. We propose that mirtazapine should be investigated further for use in PML.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17674313     DOI: 10.1086/520514

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

Review 1.  Progressive multifocal leukoencephalopathy: clinical and molecular aspects.

Authors:  Eleonora Tavazzi; Martyn K White; Kamel Khalili
Journal:  Rev Med Virol       Date:  2011-09-21       Impact factor: 6.989

Review 2.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.

Authors:  Chen S Tan; Igor J Koralnik
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

3.  Use of check-point inhibitors in the treatment of progressive multifocal leukoencephalopathy.

Authors:  Luis Miguel Juárez-Salcedo; Samir Dalia
Journal:  Ann Transl Med       Date:  2019-12

4.  Progressive multifocal leukoencephalopathy in common variable immunodeficiency: mitigated course under mirtazapine and mefloquine.

Authors:  Rebekka Kurmann; Christian Weisstanner; Piotr Kardas; Hans H Hirsch; Roland Wiest; Bernhard Lämmle; Hansjakob Furrer; Renaud Du Pasquier; Claudio L Bassetti; Mathias Sturzenegger; Heinz Krestel
Journal:  J Neurovirol       Date:  2015-04-28       Impact factor: 2.643

Review 5.  Progressive multifocal leukoencephalopathy in HIV-1 infection.

Authors:  Paola Cinque; Igor J Koralnik; Simonetta Gerevini; Jose M Miro; Richard W Price
Journal:  Lancet Infect Dis       Date:  2009-10       Impact factor: 25.071

6.  Determinants of survival in progressive multifocal leukoencephalopathy.

Authors:  A Marzocchetti; T Tompkins; D B Clifford; R T Gandhi; S Kesari; J R Berger; D M Simpson; M Prosperi; A De Luca; I J Koralnik
Journal:  Neurology       Date:  2009-11-10       Impact factor: 9.910

7.  Serotonin receptor 2A blocker (risperidone) has no effect on human polyomavirus JC infection of primary human fetal glial cells.

Authors:  Moti L Chapagain; Laarni Sumibcay; Ulziijargal Gurjav; Pakieli H Kaufusi; Richard E Kast; Vivek R Nerurkar
Journal:  J Neurovirol       Date:  2008-11-12       Impact factor: 2.643

Review 8.  Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate.

Authors:  Thorsten Bartsch; Torge Rempe; Arne Wrede; Frank Leypoldt; Wolfgang Brück; Ortwin Adams; Axel Rohr; Olav Jansen; Christian Wüthrich; Günther Deuschl; Igor J Koralnik
Journal:  Ann Neurol       Date:  2015-07-31       Impact factor: 10.422

9.  Long-Term Survival after Progressive Multifocal Leukoencephalopathy in a Patient with Primary Immune Deficiency and NFKB1 Mutation.

Authors:  Emke Maréchal; Karolien Beel; Roel Crols; Danielle Hernalsteen; Barbara Willekens
Journal:  J Clin Immunol       Date:  2020-09-11       Impact factor: 8.317

Review 10.  Update on PML: lessons from the HIV uninfected and new insights in pathogenesis and treatment.

Authors:  Elizabeth A Hartman; DeRen Huang
Journal:  Curr HIV/AIDS Rep       Date:  2008-08       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.